Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.41 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.41 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.41 |
| ▸ | CKS1B | P61024 | 1/20 | 0.41 |
| ▸ | SKP1 | P63208 | 1/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29502336 | 1.00 | PARP1 (0.45) | PARP1BACE1MAPTALDH1A1LMNA | |
| SCHEMBL23536410 | 0.91 | CYP11B2 (0.45) | PARP1BACE1ALDH1A1GPR119VCP | |
| SCHEMBL31726884 | 0.89 | CYP11B2 (0.43) | PARP1BACE1ALDH1A1GPR119USP2 | |
| SCHEMBL23536376 | 0.88 | CYP11B2 (0.46) | PARP1BACE1GPR119CCR5 | |
| SCHEMBL31701791 | 0.87 | DRD2 (0.44) | BACE1GPR119VCPCCR5 | |
| SCHEMBL27166445 | 0.84 | GPR119 (0.49) | PARP1GPR119VCP | |
| SCHEMBL30543627 | 0.82 | GPR119 (0.38) | PARP1BACE1GPR119CCR5 | |
| SCHEMBL25338742 | 0.82 | GPR119 (0.38) | PARP1BACE1GPR119CCR5 | |
| SCHEMBL25972242 | 0.82 | GPR119 (0.38) | PARP1BACE1GPR119CCR5 | |
| SCHEMBL26447780 | 0.82 | MEN1 (0.42) | MAPTALDH1A1LMNAGPR119KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117715904-A | CDK2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-117157298-A | Dual-function chimeric heterocyclic compound of interleukin-1 receptor related kinase 4, preparation method, medicinal composition and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-116867758-A | IRAK degradation agents and uses thereof | 凯麦拉医疗公司 | 2023-10-10 | — | — | CN | disclosed |
| WO-2023186069-A1 | BIFUNCTIONAL CHIMERIC HETEROCYCLIC COMPOUND OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 石药集团中奇制药技术（石家庄）有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| WO-2023278759-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| CN-114502158-A | IRAK degradation agent and application thereof | 凯麦拉医疗公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021127283-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | PARP1 1880/4885BACE1 3305/4885MAPT 2971/4885 |
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PARP1 85/4885BACE1 759/4885MAPT 2459/4885 |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PARP1 85/4885BACE1 759/4885MAPT 2459/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | PARP1 170/4885BACE1 1313/4885MAPT 2735/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PARP1 85/4885BACE1 759/4885MAPT 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.